Main > ONCOLOGY (**) > Lymphoma>NHL>B-Cell>DLBCL R/R*** > Treatment > USA. K. SINE Compound Tablets

---

USA. K. SINE Compound Tablets's subsections
(*) IL Approval Date: 2021. 02.04
(*) KR Approval Date: 2021. 08.02.
(*) SG Approval Date: 2022. 03.02
(*) USA Approval Date: 2020. 06.22.
Company
Company AU; CN; KR & SG Licensee:
Generic Name: Selinexor
Patent>Assignee; Claims; No.; Etc.
Patent>Total USA No.: 5
Patent>UpDate: 2020. 09.29.
RTM
RTM Web-Site
SINE: Selective Inhibitor of Nuclea

USA. K. SINE Compound Tablets's products
This section has no products